Most say Trump becoming more erratic: Survey

A major biotech firm announced a breakthrough therapy showing promising results in Phase 2 trials for a rare genetic disorder. The treatment aims to correct the underlying cellular mechanism and could offer a new option for patients who previously had limited choices.

Health authorities urged caution, noting the need for larger, longer-term studies to confirm safety and efficacy. Independent experts highlighted potential for accelerated approvals if preliminary data hold, but emphasized rigorous post-market monitoring.

Investors reacted with mixed sentiment as the company projected timelines for regulatory submissions, while clinicians said the findings could spark renewed interest in targeted gene therapies. Further updates are expected as ongoing trials progress and additional data become available.